Welcome to our dedicated page for Global Cord Blood SEC filings (Ticker: CORBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Global Cord Blood's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Global Cord Blood's regulatory disclosures and financial reporting.
Global Cord Blood Corporation, a Cayman Islands company under court-appointed joint provisional liquidation, filed an update about its restructuring process. The Grand Court of the Cayman Islands appointed joint provisional liquidators on September 22, 2022 under Section 104(2) of the Companies Act.
On June 1, 2026, the joint provisional liquidators furnished their sixteenth report to the Court. The report is available on the company’s investor relations website and on Grant Thornton’s creditor update page. The company also lists a regular schedule of earlier reports furnished since October 2022, indicating ongoing court-supervised oversight.
Global Cord Blood Corporation filed an update as a foreign private issuer describing the latest developments in its court-supervised provisional liquidation process in the Cayman Islands. The Grand Court previously appointed joint provisional liquidators (JPLs) for the company under the Cayman Companies Act.
On March 2, 2026, the JPLs submitted their fifteenth report to the Grand Court. The report is available to stakeholders on the company’s investor relations website and on Grant Thornton’s creditor update page. The filing also lists the dates of all prior JPL reports since October 2022, highlighting an ongoing series of structured status updates for creditors and other interested parties.
Global Cord Blood Corporation reports that its court-appointed joint provisional liquidators have submitted their fourteenth report to the Grand Court of the Cayman Islands. The liquidators were originally appointed on September 22, 2022 under the Cayman Islands Companies Act to oversee the Company’s affairs during provisional liquidation.
The new report, dated December 1, 2025, is available to the public on the Company’s investor relations website and on Grant Thornton’s creditor update page. The Company also notes that earlier reports from October 2022 through September 2025 remain accessible, providing an ongoing record of developments in the provisional liquidation process.